SOTA -  Accomplia (Rimonabant) for Rx of metabolic syndrome - 5-06
SOTA – Adults with congenital heart disease – 7-05
SOTA – Adults with congenital heart disease task force – 2-06
SOTA – Atrial fibrillation – Drug-induced – 12-04
SOTA – Alcohol and cardiovascular disease – 6-05
SOTA – Anemia in heart failure – 9-04
SOTA – Aortic stenosis intervention timing – 6-06
SOTA  - Aortic stenosis - Is it preventable? - 8-03
 

SOTA – Bayesian analysis and study interpretation – 6-04
SOTA – Behavioral cardiology – 3-05
SOTA – Biomarkers in Acute Cardiac Disease – 7-06
SOTA – Brugada Syndrome – 5-03


SOTA – CABG – Post-op Meds – 1-05
SOTA – CAD in women – 5-04
SOTA – Califf – Quality 12-02
SOTA – Cardiac resynchronization 1 – 12-05
SOTA – Cardiac resynchronization 2 – 12-05
SOTA – Choice of prosthetic valves – 3-03
SOTA – Cigarette Smoking  and CAD – 5-04
SOTA – Contrast nephropathy – 11-04

 
SOTA – Diabetes management – 8-02
SOTA – Diabetic Cardiomyopathy – fibrosis – 2-06
SOTA – Diet and cardiovascular disease – 5-05
SOTA – Disparities in cardiac care – 8-04
SOTA – Distal protection devices in PCI – 10-05
SOTA – Dyslipidemia and heart disease in women – 11-05


SOTA – Echo for resynchronization assessment – 7-04
SOTA – Endothelial dysfunction – 10-03
SOTA -  Exercise vs inflammatory markers – 5-05
SOTA – External Counterpulsation – 6-03
 

SOTA – Familial dilated cardiomyopathy – 4-05


SOTA – HDL function  - 11-05
SOTA -  HDL - Increasing HDL with medication - 1-05
SOTA  - HDL - Assessing the Significance of Low Levels - 3-04
SOTA – Heart Failure with normal LVEF – 2-04
SOTA – High-risk plaque 1 – 9-05
SOTA – High-risk plaque 2 – 10-05
SOTA – Home BP measurement – 9-05
SOTA – Hormone replacement therapy – 5-06
SOTA  - Hypertension Treatment Trials - Overview 2005 - 3-05
 

SOTA – ICD implants in clinical practice – 4-06
SOTA – Inflammatory markers and the metabolic syndrome – 12-05
SOTA – IVUS and PCI – 4-04


SOTA  - Left Atrial Size: Disease Implications - 6-06


SOTA – Management of Heart Failure after Resynchronization Therapy – 12-05
SOTA – Metabolic syndrome – 3-06
SOTA – MI reperfusion in the elderly – 2-05
SOTA – MI size quantification – 10-04
SOTA  - Myocardial Bridges - Symptomatic - 2-03
 

SOTA – Pathogenesis of diabetic atherothrombosis – 12-04
SOTA – Peripheral arterial disease in diabetes – 3-06
SOTA – Physiologic pacing – 1-06
SOTA – Plavix (clopidogrel) resistance – 4-05
SOTA – Pleiotropic effects of statins – 10-05
SOTA  - Potassium Level - optimal - 1-04
SOTA – Pregnancy and valvular disease – native – 7-05
SOTA – Pregnancy and valvular disease – prosthetic – 8-05
SOTA – Prosthetic Valves: Selection Criteria – 3-03
 

SOTA – QRS duration significance in CHF patients – 12-05


SOTA – Renal patients with CAD – 10-04
SOTA – Renal patients and cardiovascular mortality – 1-06
SOTA – Right Heart Ischemia – 9-02


SOTA – Sleep apnea and cardiac disease – 5-03
SOTA – Smallpox vaccine and myopericarditis – 5-04
SOTA – Stenting bifurcation lesions – 10-05
SOTA – Strain and strain rate imaging – 10 MB file – 4-06
SOTA – Stress echocardiography – 6-05
SOTA – Sudden death without structural heart disease – 4-04


SOTA – T-Wave alternans – 7-02
SOTA – T-Wave alternans 2 – 1-06
SOTA – Troponins in renal failure – 12-02


SOTA – Viability testing in ischemic cardiomyopathy – 8-05


SOTA – Warfarin in atrial fibrillation guidelines – 3-04
SOTA – WBC and CAD risk – 11-04
SOTA – Weather and MI in Olmstead County MN – 7-06
 

2004   -  Shortage of Cardiologists – Conference – 7-04